Drug approved for symptomatic vitreomacular adhesion

October 19, 2012
Drug approved for symptomatic vitreomacular adhesion

(HealthDay)—Jetrea (ocriplasmin) has been approved by the U.S. Food and Drug Administration to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

The condition affects the vitreous, which begins to separate from the macula. This can damage the macula, a key part of the eye's retina that's responsible for people being able to read, the FDA said Thursday in a news release.

Jetrea helps break down proteins that are responsible for VMA, preventing the need for surgery to control the condition, the agency said.

In a clinical study of 652 people, VMA resolved in 26 percent of those who took Jetrea, compared to 10 percent of cases that were resolved among those who took an inactive placebo.

The most common side effects of Jetrea were including: bleeding, pain, floaters, blurriness, vision loss, and swelling.

Jetrea is produced by ThromboGenics, based in Iselin, N.J.

Explore further: FDA approves Regeneron's eye injection Eylea

More information: The FDA has more about this approval.

Related Stories

FDA approves Regeneron's eye injection Eylea

November 19, 2011

(AP) -- Regulators on Friday approved Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat a common cause of blindness in older people.

Glaucoma stent approved

June 26, 2012

(HealthDay) -- An ocular stent that's designed to reduce inner-eye pressure among people with mild or moderate open-angle glaucoma has been approved by the U.S. Food and Drug Administration.

FDA approves drug to treat diabetic macular edema

August 13, 2012

The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, ...

Vitreolytic ocriplasmin resolves vitreomacular traction

August 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according ...

Recommended for you

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

Nearly 1 in 3 on Medicare got commonly abused opioids

June 22, 2016

Nearly 12 million Medicare beneficiaries received at least one prescription for an opioid painkiller last year at a cost of $4.1 billion, according to a federal report that shows how common the addictive drugs are in many ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.